The FDA has approved fentanyl nasal spray (Lazanda) for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. This marks the first FDA product approval for Archimedes Pharma.
The new product will be available in the second half of this year through a Risk Evaluation and Mitigation Strategy (REMS) program. Pharmacies, distributors, and health-care professionals who prescribe to outpatients are required to enroll in the program to dispense, distribute, and prescribe fentanyl nasal spray. For more information, see www.lazanda.com. ■
